Publication | Open Access
Phase II Trial of Loubo<sup>®</sup>(Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or Taxanes
62
Citations
27
References
2013
Year
The regimen of lobaplatin and pemetrexed is modestly active in metastatic breast cancer patients who failed anthracycline or taxanes, and the toxicity profile suggesting that the doses of chemotherapy should be further modified.
| Year | Citations | |
|---|---|---|
1976 | 1.3K | |
2005 | 950 | |
2012 | 74 | |
2012 | 63 | |
2011 | 59 | |
2011 | 59 | |
1993 | 55 | |
2012 | 54 | |
2011 | 51 | |
2012 | 51 |
Page 1
Page 1